The Pharma Letter20h
GSK’s Nucala wins wider approval in China
China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK ...
The Pharma Letter20h
WuXi Biologics works with Sino on first-in-class antibody
WuXi Biologics has signed a deal with Sino Biopharm to develop a first-in-class monoclonal antibody targeting an undisclosed ...
The Pharma Letter21h
2024 pharma and biotech M&A deals exceed 2023 in numbers but not value
Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – ...
The Pharma Letter20h
PrimeGene secures $46 million in series B financing
PrimeGene raises $46 million in a series B round to advance Phase III trials and regulatory filings for pumecitinib, its atopic dermatitis treatment. Funds will also support pipeline expansion and IPO ...
The Pharma Letter22h
Chugai gains Japanese regulatory approval for Lunsumio
Japanese drugmaker Chugai Pharmaceuticals has obtained regulatory approval from the Ministry of Health, Labor and Welfare (MHLW) for Lunsumio (mosunetuzumab) for intravenous infusion 1mg and 30mg for ...
The Pharma Letter1d
Set a new password
39-43 Putney High Street, Putney London, SW15 1SP United Kingdom ...